saplin

HDFC Pharma and Healthcare Fund

HDFC Pharma and Healthcare Fund (Direct, Growth): saplin Score 9.1/10 (Strong) among 14 Sectoral/Thematic funds. 3Y return 31.1% a year vs 21.9% category median, expense ratio 1.01%. Returns that beat most peers, with nothing standing out as a weakness. NAV ₹23.42 on 11 Nov 2026.

Loading the full analysis…

Questions about HDFC Pharma and Healthcare Fund

What is the expense ratio of HDFC Pharma and Healthcare Fund?

The Direct plan's total expense ratio is 1.01% a year, against a median of 1.04% for sectoral/thematic funds. The Regular plan costs more because it pays a distributor's commission.

Who manages HDFC Pharma and Healthcare Fund?

Nikhil Mathur (since 4 Oct 2023); Gopal Agrawal (since 1 Sept 2026); Bhagyesh Kagalkar (since 26 Aug 2026).

What are the top holdings of HDFC Pharma and Healthcare Fund?

Divis Laboratories 9.44%, Sun Pharmaceutical Industries 7.74%, Dr Reddys Laboratories 6.66%, Apollo Hospitals Enterprise 5.19%, Alkem Laboratories 4.75% of the portfolio, as of 31 Oct 2026.

What returns has HDFC Pharma and Healthcare Fund given?

1 year: 32.2% (category median 21.9%); 3 years: 31.1% a year (category median 21.9%). Past returns do not predict future ones.

How big is HDFC Pharma and Healthcare Fund?

About ₹3,128 cr (AMFI's average for the latest quarter).

How does HDFC Pharma and Healthcare Fund score?

9.1 out of 10 (Strong) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on HDFC Pharma and Healthcare